Chips, Clones, and Living Beyond 100 How Far Will the Biosciences Take Us?
, by Schoemaker, Paul J. H.; Schoemaker, Joyce A.- ISBN: 9780137153855 | 0137153856
- Cover: Hardcover
- Copyright: 9/8/2009
Paul J. H. Schoemaker, Ph.D. is Research Director of the Mack Center for Technological Innovation at The Wharton School, where he teaches strategy and decision making. Dr. Schoemaker is also the founder and chairman of Decision Strategies International, Inc., a consulting and training firm specializing in strategic planning and executive development. He has written more than 100 academic and applied papers as well as coauthored numerous books, including Decision Traps, Wharton on Managing Emerging Technologies, Winning Decisions, Profiting from Uncertainty, and Peripheral Vision. He serves on multiple boards.
Joyce A. Schoemaker, Ph.D. has conducted basic research in microbiology and molecular genetics at the University of Chicago and taught microbiology at Villanova University. She has held positions in research and management at several biotechnology companies, including Celltech in London, and has published numerous scientific articles in biology. She is coauthor of Healthy Homes, Healthy Kids: Protecting Your Children From Everyday Environmental Hazards. Dr. Schoemaker has a long-standing interest in environmental issues as well as the emerging biosciences.
Foreword | p. xii |
Preface | p. xiv |
Living well beyond 100 | p. 1 |
Great progress made, much more to come | p. 1 |
Medical challenges and promises | p. 4 |
Living well versus living longer | p. 7 |
Social challenges and promises | p. 10 |
Can we afford old age? | p. 11 |
Government and business | p. 13 |
The journey ahead | p. 17 |
A short history of biomedicine | p. 21 |
Improving hygiene | p. 21 |
The power of immunology | p. 23 |
Monoclonal antibodies | p. 24 |
The discovery of antibiotics | p. 25 |
The DNA revolution | p. 26 |
Recombinant DNA and cloning | p. 27 |
Biotechnology | p. 29 |
Unraveling the code | p. 31 |
Conclusion | p. 33 |
Snapshot of the biosciences | p. 35 |
DNA-based technologies | p. 35 |
Genomics | p. 37 |
Genetic testing | p. 37 |
DNA chips | p. 39 |
Pharmacogenetics | p. 40 |
Cloning | p. 41 |
Gene therapy | p. 43 |
RNA-based technologies | p. 45 |
Antisense technology | p. 45 |
RNA interference (RNAi) | p. 46 |
Protein-based technologies | p. 46 |
Vaccines | p. 47 |
Monoclonal Antibodies | p. 48 |
Proteomics | p. 49 |
Cell-based and other technologies | p. 50 |
Stem cells | p. 50 |
Antimicrobials | p. 51 |
Conclusion | p. 52 |
Bio-driven convergence | p. 57 |
Converging technologies | p. 58 |
Telemedicine | p. 58 |
Remote diagnostics | p. 59 |
Biological drug factories | p. 59 |
Biochips | p. 59 |
Tissue engineering | p. 60 |
Imaging | p. 61 |
Multidirectional synergies | p. 62 |
Shifting industry boundaries | p. 64 |
Healthcare and IT | p. 65 |
Medical information handling | p. 65 |
Medical data storage | p. 66 |
Computers and drug discovery | p. 66 |
Remote monitoring and the wired home | p. 67 |
Reshaping bioinformatics | p. 67 |
Bioinformatics and gene banks | p. 69 |
Personalized medicine | p. 70 |
Systems biology and holistic medicine | p. 70 |
Biosensors | p. 72 |
Nano devices | p. 72 |
Commercialization challenges | p. 73 |
Technological challenges: biocompatibility | p. 74 |
Regulatory challenges: clinical safety and efficacy | p. 74 |
Political challenges: privacy and ownership | p. 74 |
Social challenges: consumer advocacy | p. 75 |
The road ahead | p. 76 |
The business of biomedicine | p. 79 |
The pharmaceutical industry | p. 79 |
Diminishing drug pipelines | p. 82 |
The biotechnology sector | p. 85 |
Medical device industry | p. 89 |
Cardiovascular device segment | p. 89 |
Orthopedic device segment | p. 91 |
Neurological device segment | p. 91 |
Medical diagnostics industry | p. 92 |
Laboratory testing | p. 93 |
Point-of-care (POC) patient monitoring and diagnosis | p. 94 |
Prevention and disease management | p. 95 |
Conclusions | p. 97 |
Healthcare under stress | p. 101 |
Stress in developed nations | p. 103 |
Healthcare funding | p. 104 |
Major diseases of the developed world | p. 105 |
Cardiovascular diseases | p. 106 |
Cancer | p. 106 |
Stress in developing nations | p. 107 |
Acquired Immune Deficiency Syndrome (AIDS) | p. 109 |
Malaria | p. 111 |
Which technologies will succeed? | p. 113 |
Illustrative cases | p. 114 |
AIDS and malaria | p. 115 |
Cardiovascular diseases | p. 115 |
Cancer | p. 116 |
Wildcards for the future | p. 125 |
Trends versus uncertainties | p. 125 |
Wildcards | p. 127 |
Society and politics | p. 127 |
Public support of the biosciences? | p. 127 |
A major pandemic? | p. 129 |
Biotech rogue states? | p. 130 |
Science and technology | p. 131 |
Raging success or major meltdown? | p. 131 |
Role of complementary industries? | p. 132 |
Intellectual property regimes? | p. 133 |
Qualified staff for healthcare and research? | p. 133 |
Business and economics | p. 134 |
Economic growth and global power shifts? | p. 134 |
Venture capital and other funding sources? | p. 135 |
Climate change and resource scarcity? | p. 135 |
A scenario framework | p. 136 |
The first overarching uncertainty: technological success | p. 137 |
The second overarching uncertainty: societal acceptance | p. 137 |
Multiple scenarios are possible | p. 138 |
The role of stakeholders | p. 141 |
Scenarios up to 2025 | p. 143 |
Bio gridlock scenario | p. 143 |
The view from 2025 | p. 143 |
How we got here | p. 145 |
The world we live in | p. 150 |
Analogous cases: Nuclear power, GMOs | p. 151 |
Golden age scenario | p. 153 |
The view from 2025 | p. 154 |
How we got here | p. 154 |
The world we live in | p. 158 |
Analogous case: information technology | p. 160 |
What it all means | p. 163 |
You and your family | p. 163 |
At work | p. 168 |
Business and commerce | p. 170 |
Society at large | p. 172 |
DNA, RNA, and protein | p. 177 |
Molecules of inheritance | p. 177 |
The structure of DNA | p. 178 |
Cracking the code | p. 179 |
Making proteins | p. 180 |
Regulating gene expression | p. 181 |
Cloning genes | p. 183 |
Restriction enzymes | p. 183 |
Cloning procedure | p. 184 |
Complexity of the genome | p. 187 |
Non-Coding RNAs | p. 187 |
SNP variations | p. 188 |
Glossary of Biomedical Terms | p. 191 |
Acknowledgments | p. 199 |
About the Authors | p. 201 |
Index | p. 203 |
Table of Contents provided by Ingram. All Rights Reserved. |
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.
Digital License
You are licensing a digital product for a set duration. Durations are set forth in the product description, with "Lifetime" typically meaning five (5) years of online access and permanent download to a supported device. All licenses are non-transferable.
More details can be found here.